Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | KIF20A | O95235 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9360828 | 0.82 | F7 (0.51) | APPCLK1DYRK1AF7F3 | |
| SCHEMBL9360837 | 0.82 | F7 (0.51) | APPCLK1DYRK1AF7F3 | |
| SCHEMBL3249611 | 0.82 | APP (0.63) | APPMEN1KMT2ANR4A2HTR2A | |
| SCHEMBL3244418 | 0.82 | APP (0.63) | APPGPR84MEN1KMT2ANR4A2 | |
| SCHEMBL4328855 | 0.78 | APP (1.00) | APPKIF20AMEN1KMT2ATRPA1 | |
| SCHEMBL28422000 | 0.77 | GPR84 (0.56) | F7F3GPR84TDO2NR4A2 | |
| SCHEMBL3246996 | 0.76 | APP (0.56) | APPMEN1KMT2APOLBMAPT | |
| SCHEMBL4185864 | 0.76 | MAPT (0.47) | APPCLK1DYRK1AF7F3 | |
| SCHEMBL4185859 | 0.76 | MAPT (0.47) | APPCLK1DYRK1AF7F3 | |
| SCHEMBL4185862 | 0.76 | MAPT (0.47) | APPCLK1DYRK1AF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | claimed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | claimed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | disclosed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | disclosed |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | disclosed |
| EP-3164125-B1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN GLOBAL LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | disclosed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | disclosed |
| US-10849872-B2 | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes | NAN Global, LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | disclosed |
| EP-1575575-B1 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-1575575-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-09-21 | — | — | EP | disclosed |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-15 | — | — | US | disclosed |
| WO-2004041256-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | APP 3048/4885CLK1 110/4885DYRK1A 1065/4885 |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | APP 3048/4885CLK1 110/4885DYRK1A 1065/4885 |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | PC, CPT2, IDH2 | APP 4565/4885CLK1 4379/4885DYRK1A 3659/4885 |
| US-10849872-B2 | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes | GPR119, CPT1B, CPT2 | APP 3048/4885CLK1 110/4885DYRK1A 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.